Dr. Christopher Klein

Dr. Christopher Klein is a partner at Steinbeis M&A Partners GmbH with a committed focus on Healthcare.

He learnt the M&A gamut at Arthur Andersen and Ernst & Young, then moved to the industry for 20 years as a corporate developer and executive manager (pharma-biotech-medtech of all sizes) and returned to the advisory profession in 2024.

Previously, Christopher was:

• Managing Director / CFO – Numaferm
• Chief Corporate Development Officer – Hameln Pharma
• Vice-President Business Development – Paul Hartmann Group
• Head Global M&A – Novartis-Sandoz
• CFO / Head Global BD&L – Sandoz Biopharmaceuticals
• Manager – Ernst & Young Corporate Finance
• Analyst / Associate – Arthur Andersen Corporate Finance
• Assistent – Biotechnology Unit of European Commission

He holds degrees in biotechnology and business administration following his studies at TU Braunschweig, FernUni Hagen, University College London and Technical University of Denmark.

Due to his cultural interests and family, he is multilingual and a cosmopolitan. His heart beats for trains. In addition to railway and traveling, he also enjoys photography, baroque music and outdoor activities.